Page 255 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 255
P0781 HIGH SVR RATES DESPITE MULTIPLE NEGATIVE ePOSTERS
P0782 PREDICTORS IN GENOTYPE 1 PATIENTS RECEIVING
P0783 OMBITASVIR/PARITAPREVIR/R, DASABUVIR WITH OR
P0784 WITHOUT RIBAVIRIN FOR 12 AND 24 WEEKS: INTEGRATED
ANALYSIS OF SIX PHASE 3 TRIALS
Nancy Reau, Michael W. Fried, Heiner Wedemeyer, Curtis Cooper,
Moisés Diago, Antonio Craxi, Simone Strasser, Jean-Francois Dufour,
Wangang Xie, Lois Larsen, Emily O. Dumas, David Bernstein*,
The United States
ALL-ORAL 12-WEEK COMBINATION TREATMENT
WITH DACLATASVIR (DCV) AND SOFOSBUVIR (SOF) IN
TREATMENT-EXPERIENCED PATIENTS INFECTED WITH
HCV GENOTYPE (GT) 3: A SUBANALYSIS OF THE ALLY-3
PHASE 3 STUDY
David Nelson*, David Bernstein, Bradley Freilich, Eric Lawitz,
Trevor Hawkins, Paul Pockros, Paul Thuluvath, Ziad Younes,
Michael Bennett, Reem Ghalib, Peter J. Ruane, Myron Tong,
Rafia Bhore, Philip D. Yin, Stephanie Noviello, Khurram Rana,
The United States
VIRAL KINETICS DURING INTERFERON-FREE
SOFOSBUVIR CONTAINING TREATMENT REGIMENS IN A
REAL-LIFE COHORT OF CHRONIC HEPATITIS C PATIENTS
WITH ADVANCED LIVER DISEASE
Karin Kozbial*, Clarissa Freissmuth, Robert Strassl, Ramona Al-
Zoairy, Andreas Maieron, Rudolf Stauber, Michael Gschwantler,
Michael Strasser, Hermann Laferl, Thomas Bamberger, Stephan Moser,
Michael Eder, Sandra Beinhardt, Albert F. Staettermayer,
Mattias Mandorfer, Arnulf Ferlitsch, Heinz Zoller, Peter Knoflach,
Katharina Staufer, Markus Peck-Radosavljevic, Petra Munda,
Wolfgang Vogel, Peter Ferenci, Harald Hofer, Austria
SOFOSBUVIR IN COMBINATION WITH PEGINTERFERON
AND RIBAVIRIN FOR PATIENTS CHRONICALLY INFECTED
WITH HEPATITIS C VIRUS GENOTYPE 4: “REAL-LIFE”
EXPERIENCE OF TWO LARGE VIRAL HEPATITIS CENTERS
IN NORTHERN GERMANY
Malte H. Wehmeyer*, Sabine Jordan, Christiane Eißing, Johannes Hartl,
Albrecht Stöhr, Jörg Petersen, Ansgar W. Lohse, Stefan Lüth,
Peter Buggisch, Julian Schulze zur Wiesch, Germany
Vienna, Austria • April 22–26, 2015 255
P0782 PREDICTORS IN GENOTYPE 1 PATIENTS RECEIVING
P0783 OMBITASVIR/PARITAPREVIR/R, DASABUVIR WITH OR
P0784 WITHOUT RIBAVIRIN FOR 12 AND 24 WEEKS: INTEGRATED
ANALYSIS OF SIX PHASE 3 TRIALS
Nancy Reau, Michael W. Fried, Heiner Wedemeyer, Curtis Cooper,
Moisés Diago, Antonio Craxi, Simone Strasser, Jean-Francois Dufour,
Wangang Xie, Lois Larsen, Emily O. Dumas, David Bernstein*,
The United States
ALL-ORAL 12-WEEK COMBINATION TREATMENT
WITH DACLATASVIR (DCV) AND SOFOSBUVIR (SOF) IN
TREATMENT-EXPERIENCED PATIENTS INFECTED WITH
HCV GENOTYPE (GT) 3: A SUBANALYSIS OF THE ALLY-3
PHASE 3 STUDY
David Nelson*, David Bernstein, Bradley Freilich, Eric Lawitz,
Trevor Hawkins, Paul Pockros, Paul Thuluvath, Ziad Younes,
Michael Bennett, Reem Ghalib, Peter J. Ruane, Myron Tong,
Rafia Bhore, Philip D. Yin, Stephanie Noviello, Khurram Rana,
The United States
VIRAL KINETICS DURING INTERFERON-FREE
SOFOSBUVIR CONTAINING TREATMENT REGIMENS IN A
REAL-LIFE COHORT OF CHRONIC HEPATITIS C PATIENTS
WITH ADVANCED LIVER DISEASE
Karin Kozbial*, Clarissa Freissmuth, Robert Strassl, Ramona Al-
Zoairy, Andreas Maieron, Rudolf Stauber, Michael Gschwantler,
Michael Strasser, Hermann Laferl, Thomas Bamberger, Stephan Moser,
Michael Eder, Sandra Beinhardt, Albert F. Staettermayer,
Mattias Mandorfer, Arnulf Ferlitsch, Heinz Zoller, Peter Knoflach,
Katharina Staufer, Markus Peck-Radosavljevic, Petra Munda,
Wolfgang Vogel, Peter Ferenci, Harald Hofer, Austria
SOFOSBUVIR IN COMBINATION WITH PEGINTERFERON
AND RIBAVIRIN FOR PATIENTS CHRONICALLY INFECTED
WITH HEPATITIS C VIRUS GENOTYPE 4: “REAL-LIFE”
EXPERIENCE OF TWO LARGE VIRAL HEPATITIS CENTERS
IN NORTHERN GERMANY
Malte H. Wehmeyer*, Sabine Jordan, Christiane Eißing, Johannes Hartl,
Albrecht Stöhr, Jörg Petersen, Ansgar W. Lohse, Stefan Lüth,
Peter Buggisch, Julian Schulze zur Wiesch, Germany
Vienna, Austria • April 22–26, 2015 255
